Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that the ...

Nuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naïve ALK-positive NSCLC ...

The initiation of the registration-directed ALKAZAR study enables us to explore this potential by comparing neladalkib to a front-line standard of care in a randomized, controlled clinical trial ...

The ALKAZAR trial is designed to enroll approximately 450 TKI-naïve patients with advanced ALK-positive NSCLC. Patients will be randomized 1:1 to receive neladalkib monotherapy or alectinib ...

The study will compare neladalkib to Genentech's ALK inhibitor Alecensa in patients who've had no prior systemic treatment.

Contribute to Prashant-codes/Hotel-ALKAZAR development by creating an account on GitHub.

Contribute to Prashant-codes/Hotel-ALKAZAR development by creating an account on GitHub.

Get the latest Nuvalent, Inc. (NUVL) stock news and headlines to help you in your trading and investing decisions.

– MOMA-341 is a highly differentiated, potentially best-in-class oral covalent Werner helicase inhibitor with a novel chemical scaffold identified via the KNOMATIC™ platform – CAMBRIDGE, MA, USA I ...